Obermatt

Lupin

NSI:LUPIN · INE326A01037
PharmaceuticalsX-Large

360

67
EV / EBIT44
Price / Owner Earnings54
Owner Earnings Yield62
Dividend Yield47
Price/Sales44
EV / Gross Profit66
Price/Book31
Return on Capital87
Cash Return on Capital88
Return on Equity87
EBIT Margin69
Gross Profitability79
Cash Conversion63
Owner Earnings Margin59
Sales growth21
Profit Growth91
Long-Term EPS Growth88
Reinvestment63
Price momentum59
Debt load44
Refinancing39
Debt Payback100
Liquidity54
Analyst ratings32
Opinion Changes23
Price Target Upside42
Market mood69
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Lupin generates returns well above its cost of capital, the foundation of durable shareholder value.

Based on 3/5 components.

Profile

CountryIndia
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeBSE
Founded1983
Employees10,765
Websitelupin.com
ISININE326A01037
Last UpdateApr 2, 2026
Index & Theme
BiotechnologyPharmaceutical

Description

Analysis

Quality compounder

Lupin Limited is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is fair. You pay 21.0× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 7% yearly growth; analysts expect 20%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is adequate. The company scores 20/20 on our value-creation score: strong value creator.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
37
2023202420252026

All-time high

82

Mar 2026

All-time low

1

Jan 2023

Average rank

46

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
44
52
64
72
Price/Earnings
63
54
41
41
Price/Book
31
39
47
67
Dividend Yield
47
33
30
34
Value (overall)
56
43
49
53

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Lupin with its peers
Cipla
NSI:CIPLA
53
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Torrent Pharmaceuticals
NSI:TORNTPHARM
18
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Glenmark Pharmaceuticals
NSI:GLENMARK
58
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Aurobindo Pharma
NSI:AUROPHARMA
60
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Ajanta Pharma
NSI:AJANTPHARM
65
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Alkem Laboratories
NSI:ALKEM
47
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →